Sugi Predict

Sugi Predict / Compounds / SCHEMBL1473066

SCHEMBL1473066

SCHEMBL1473066

CN(C)C(=O)CN1CCOCC1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.55
▸ HSD17B10 Q99714 2/20 0.55
▸ TSHR P16473 2/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ ALDH1A1 P00352 4/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ MAPT P10636 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HRH3 Q9Y5N1 1/20 0.43
▸ GLA P06280 1/20 0.42
▸ LMNA P02545 3/20 0.42
▸ TP53 P04637 1/20 0.42
▸ RAB9A P51151 1/20 0.41
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15532918 0.84 KDM4E (0.57) KDM4EHSD17B10TSHRALOX15ALDH1A1
SCHEMBL20709048 0.84 KDM4E (0.52) KDM4EHSD17B10TSHRALOX15ALDH1A1
SCHEMBL19000031 0.82 KDM4E (0.50) KDM4EHSD17B10TSHRALOX15ALDH1A1
SCHEMBL12510959 0.82 KDM4E (0.50) KDM4EHSD17B10TSHRALOX15ALDH1A1
SCHEMBL13227061 0.81 KDM4E (0.48) KDM4EHSD17B10TSHRALOX15ALDH1A1
SCHEMBL31242949 0.81 KDM4E (0.48) KDM4EHSD17B10TSHRALOX15ALDH1A1
SCHEMBL8290941 0.80 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HTT
SCHEMBL4958458 0.80 ALDH1A1 (0.56) KDM4EALDH1A1LMNARAB9AHTT
SCHEMBL2910116 0.80 GLA (0.58) KDM4EHSD17B10TSHRALDH1A1SMN1; SMN2
SCHEMBL26343664 0.80 SIGMAR1 (0.48) KDM4EHSD17B10TSHRALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1126843-A4 COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME BRISTOL MYERS SQUIBB CO (US) 2005-06-15 — — EP claimed
EP-1126843-A1 COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2001-08-29 — — EP claimed
WO-2000025780-A1 COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2000-05-11 — — WO claimed
WO-2023250513-A1 13-MEMBERED MACROLIDE COMPOUNDS FOR TREATING DISEASES MEDIATED BY ABNORMAL PROTEIN TRANSLATION ZIKANI THERAPEUTICS, INC. (US) 2023-12-28 — — WO disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 — — US disclosed
CN-111491930-B Substituted Indole Compounds Useful as TLR Inhibitors 百时美施贵宝公司 2023-09-26 — — CN disclosed
WO-2021197467-A1 MULTI-TARGET ANTI-TUMOR COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 上海华汇拓医药科技有限公司 2021-10-07 — — WO disclosed
US-20170174653-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-06-22 — — US disclosed
WO-2017106607-A1 POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS MERCK PATENT GMBH (DE) 2017-06-22 — — WO disclosed
WO-2014041518-A1 THIENOPYRROLE DERIVATIVES AS ITK INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2014-03-20 — — WO disclosed
US-7915255-B2 Metabolism-modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2011-03-29 — — US disclosed
US-7524863-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-28 — — US disclosed
US-7199149-B2 Monocyclic and bicyclic lactams as factor Xa inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2007-04-03 — — US disclosed
US-7199149-B2 Monocyclic and bicyclic lactams as factor Xa inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2007-04-03 — — US disclosed
US-7157470-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 — — US disclosed
US-7157470-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 — — US disclosed
WO-2005032468-A2 MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-14 — — WO disclosed
WO-2004041776-A2 SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-21 — — WO disclosed
EP-0452392-A1 HETEROCYCLIC CHELATING AGENTS. NYCOMED AS (NO) 1991-10-23 — — EP disclosed
US-4737498-A N-alkyl-2,6-dimethylmorpholinocarboxamide salts, compositions and their use as fungicides BASF AKTIENGESELLSCHAFT (DE) 1988-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 KDM4E 1863/4885HSD17B10 3751/4885TSHR 791/4885
US-20170174653-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 KDM4E 1982/4885HSD17B10 3851/4885TSHR 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.